Project Lead(s): Tendayi Kureya
Despite the progress having been made in malaria control, more than 16 million people remain at risk of malaria in Zambia. In an effort to reduce preventable mortality and morbidity from severe malaria among children aged six months to six years, MAMaZ Against Malaria will introduce pre-referral rectal artesunate suppositories, a life-saving drug for the treatment of severe malaria, in hard-to-reach communities in Zambia.